###begin article-title 0
###xml 57 65 <span type="species:ncbi:9606">children</span>
GH responsiveness in a large multinational cohort of SGA children with short stature (NESTEGG) is related to the exon 3 GHR polymorphism
###end article-title 0
###begin p 1
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
###end p 1
###begin title 2
Objective
###end title 2
###begin p 3
###xml 139 144 <span type="species:ncbi:9606">human</span>
###xml 172 180 <span type="species:ncbi:9606">children</span>
###xml 361 369 <span type="species:ncbi:9606">children</span>
The polymorphic deletion of exon 3 of the GH receptor (d3-GHR) has recently been linked to the magnitude of growth response to recombinant human GH (rhGH) therapy in short children with or without GH deficiency. We investigated this association in a large multinational cohort from the Network of European Studies of Genes in Growth (NESTEGG), comprising short children born small for gestational age (SGA).
###end p 3
###begin title 4
Design
###end title 4
###begin p 5
###xml 41 49 <span type="species:ncbi:9606">children</span>
The study included short prepubertal SGA children treated with rhGH for 1 or 2 years.
###end p 5
###begin title 6
Population
###end title 6
###begin p 7
###xml 42 50 <span type="species:ncbi:9606">children</span>
Two hundred and forty white Caucasian SGA children (138 male, 102 female) aged 6.6 +/- 2.3 years with a height at -3.0 +/- 0.7 SDS at start of rhGH treatment; 193 ethnically matched controls.
###end p 7
###begin title 8
Methods
###end title 8
###begin p 9
The GHR polymorphism (fl/fl, fl/d3 or d3/d3) was genotyped by polymerase chain reaction (PCR) multiplex assay. Growth velocity (G/V) in cm/year and changes in GV during the first and second year of rhGH treatment were evaluated.
###end p 9
###begin title 10
Results
###end title 10
###begin p 11
###xml 108 109 108 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 141 142 141 142 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 418 419 418 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 50 58 <span type="species:ncbi:9606">children</span>
###xml 290 298 <span type="species:ncbi:9606">children</span>
###xml 335 343 <span type="species:ncbi:9606">children</span>
The change in GV was significantly greater in SGA children carrying one or two copies of the d3-GHR allele (P = 0.038 for the first year and P = 0.041 for the second year of GH treatment), but the change in height was not significantly different. Birthweight was significantly lower in SGA children with the d3/d3 genotype than in SGA children with the fl/fl genotype (P = 0.034) and in those with the fl/d3 genotype (P = 0.016).
###end p 11
###begin title 12
Conclusion
###end title 12
###begin p 13
###xml 134 142 <span type="species:ncbi:9606">children</span>
Our data, based on a large cohort, showed that the exon 3 GHR polymorphism is associated with responsiveness to rhGH treatment in SGA children with short stature.
###end p 13
###begin title 14
Introduction
###end title 14
###begin p 15
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 387 388 387 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 687 688 687 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 906 907 906 907 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 1104 1105 1104 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 1356 1357 1356 1357 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1399 1400 1399 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1408 1409 1408 1409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 1498 1499 1498 1499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1515 1516 1515 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 1524 1525 1524 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 1599 1600 1599 1600 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 1720 1721 1720 1721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 24 29 <span type="species:ncbi:9606">human</span>
###xml 69 77 <span type="species:ncbi:9606">children</span>
###xml 1214 1222 <span type="species:ncbi:9606">children</span>
###xml 1250 1258 <span type="species:ncbi:9606">children</span>
###xml 1309 1317 <span type="species:ncbi:9606">children</span>
###xml 1554 1562 <span type="species:ncbi:9606">children</span>
###xml 1736 1744 <span type="species:ncbi:9606">children</span>
Response to recombinant human growth hormone (rhGH) therapy in short children without GH deficiency is variable1, 2 and the prediction of this response may not be accurate. Prediction models based on variables such as age, weight, parental height and rhGH dosage only explain half of the response to rhGH, suggesting the existence of genetic and environmental determinants still unknown.3 GH acts at the target cell through the GH receptor, which, after binding of the ligand, stimulates a signalling cascade that leads to target genes transcription. This receptor contains an unusual genetic polymorphism caused by a genomic deletion of exon 3 (d3-GHR) that mimics alternative splicing.4 This deletion results in the loss of amino acid residues 7-28 and the amino acid substitution A6D at the N-terminal part of the extracellular domain, although the deleted protein does not have altered affinity for GH.5 It has been demonstrated, in transfection experiments, that the transduction of GH signalling through d3-GHR homo- or heterodimers was almost 30% higher than through the full-length GHR homodimer.6 These data corroborate the association of the d3-GHR variant with increased responsiveness to rhGH in short children without GH deficiency. The children genotyped in this first report consisted of short children born small for gestational age (SGA) (n = 60) and with idiopathic short stature (n = 112).6 Another publication has confirmed the increased rhGH responsiveness in Turner syndrome (n = 53) and SGA (n = 60), 7 but a recent study of short children born SGA did not confirm these data.8 We have investigated this association in the cohort from the Network of European Studies of Genes in Growth (NESTEGG), 9 consisting of children from four different countries (France, the Netherlands, the UK and Germany).
###end p 15
###begin title 16
Subjects and methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 385 386 385 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 105 113 <span type="species:ncbi:9606">children</span>
###xml 124 132 <span type="species:ncbi:9606">children</span>
The NESTEGG project, which had been approved in all countries by their own ethical committees, recruited children born SGA, children with idiopathic short stature and controls across four different countries (France, the Netherlands, the UK and Germany) according to a standard protocol where detailed phenotypic features were recorded and blood sampling was undertaken to provide DNA.9
###end p 18
###begin p 19
###xml 42 43 42 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 32 40 <span type="species:ncbi:9606">children</span>
###xml 288 296 <span type="species:ncbi:9606">children</span>
Prepubertal white Caucasian SGA children (n = 240) with short stature (height SDS </= -1.88 and/or weight SDS </= -1.88) treated with rhGH for at least 1 year were included in the present analysis. We chose the cut-off of -1.88 instead of -2 SDS to avoid the exclusion of some borderline children. Exclusion criteria were a known syndrome or dysmorphic features, known chromosomal or genetic abnormality, known severe chronic illness or endocrine disease or positive gliadin, endomysial or reticulin antibodies, and severe disproportionate short stature.
###end p 19
###begin p 20
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 422 429 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 930 931 912 913 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 4 12 <span type="species:ncbi:9606">children</span>
###xml 339 347 <span type="species:ncbi:9606">children</span>
###xml 453 457 <span type="species:ncbi:9606">boys</span>
###xml 465 470 <span type="species:ncbi:9606">girls</span>
###xml 829 837 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">children</span>
All children were evaluated at baseline and every 3 months during rhGH treatment. Evaluations included measurements of weight (using a digital scale), standing height (standing height was the mean of three measurements with a Harpenden stadiometer) and pubertal status graded according to Marshall and Tanner.10, 11 One hundred and ninety children were treated for 2 years. The phenotypic characteristics are presented in Table 1. The sex ratio was 138 boys to 102 girls with a mean birth length of -2.9 +/- 1.4 SDS and birthweight of -2.3 +/- 1.0 SDS. Mean maternal height was -1.0 +/- 1.3 SDS and mean paternal height -0.8 +/- 1.0 SDS. Age at onset of rhGH treatment was 6.6 +/- 2.3 years with a mean height of -3.0 +/- 0.7 SDS and a mean weight of -2.4 +/- 0.9 SDS. The mean rhGH dose was 0.4 +/- 0.17 mg/kg/week. Forty-three patients received a replacement rhGH dose (0.21 +/- 0.04 mg/kg/week) while the majority of children (n = 197) received a higher dose of rhGH (0.43 +/- 0.17 mg/kg/week).
###end p 20
###begin p 21
###xml 45 46 45 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Phenotype and genotype of NESTEGG short SGA (n = 240) and controls (n = 193). Data are presented as mean +/- SD or percentage
###end p 21
###begin title 22
Growth prediction
###end title 22
###begin p 23
###xml 100 105 100 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 106 107 106 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 358 363 358 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b13">13</xref>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 9 14 <span type="species:ncbi:9606">child</span>
###xml 445 453 <span type="species:ncbi:9606">children</span>
For each child, a growth prediction for the first year of therapy was calculated according to Ranke et al.2 The prediction model incorporates rhGH dose, age and weight at start of therapy (given in SDS according to Freeman et al.12) as well as gender-adjusted midparental height (MPH) (in SGA) or the distance to MPH (given in height SDS according to Tanner et al.13, 14) as the main prognostic factors. The equation for prediction in short SGA children is: growth during the first year (cm) = 9.4 + [56.51 x rhGH dose (mg/kg/day)] + [-0.31 x age at onset (years)] + [0.30 x body weight SDS at start] + [0.11 x MPH SDS].
###end p 23
###begin p 24
###xml 134 135 134 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 124 132 <span type="species:ncbi:9606">children</span>
The individual deviations from the prediction were divided by the standard error of the prediction, which is 1.30 cm in SGA children, 2 resulting in the studentized residuals. A studentized residual of 0 means that the prediction was completely fulfilled. Positive values indicate growth exceeding the prediction, negative values are the expression of growth slower than predicted.
###end p 24
###begin title 25
Controls
###end title 25
###begin p 26
The controls were of white Caucasian descent and were recruited in early to mid-adulthood according to a standard protocol, where auxological details (birth length, birthweight, gestational age, current weight and height, blood pressure, current medical history and medication) were recorded and a blood sample was drawn for DNA extraction.
###end p 26
###begin title 27
Molecular studies
###end title 27
###begin p 28
###xml 293 298 293 298 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Genomic DNA was isolated from peripheral blood leucocytes by standard methods from all patients. The frequency of the GHR transcript variant [full-length (fl) or exon 3 deleted (d3)] was tested in all subjects using a simple multiplex polymerase chain reaction (PCR) assay described by Pantel et al.4 Amplification products were analysed by electrophoresis on a 1% agarose gel stained with ethidium bromide. The fl-GHR is represented by a 935-bp fragment and the d3-GHR by a 532-bp fragment.
###end p 28
###begin title 29
Statistical analysis
###end title 29
###begin p 30
###xml 143 151 <span type="species:ncbi:9606">Patients</span>
Qualitative variables are listed as frequencies and percentages, whereas quantitative variables are shown as mean +/- SD, or median and range. Patients were divided by genotype and compared with regard to continuous parameters (e.g. age, midparental height in SDS, height at start of treatment in SDS, birth length and birthweight in SDS, paternal and maternal height in SDS), as well as changes in height velocity.
###end p 30
###begin p 31
###xml 212 213 212 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 215 216 215 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 272 280 <span type="species:ncbi:9606">children</span>
The response to rhGH was evaluated by annual growth velocities (in cm/year) and by the differences between growth velocity before GH treatment and during the first and/or second year of GH treatment as published.6, 7 Height velocity expressed in SDS was not chosen as all children were prepubertal and there was no sex difference at this age.
###end p 31
###begin p 32
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 82 90 <span type="species:ncbi:9606">patients</span>
The d3/d3 and d3/fl patients were grouped together (group D) to compare them with patients with the fl/fl genotype.
###end p 32
###begin p 33
###xml 109 110 109 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Comparisons between groups were made by the Mann-Whitney test or the Kruskall-Wallis test, as appropriate. A P-value of less than 0.05 was considered statistically significant. All statistical analyses were performed with Statview for Windows.
###end p 33
###begin title 34
Results
###end title 34
###begin title 35
Distribution of d3-GHR and fl-GHR
###end title 35
###begin p 36
###xml 56 59 56 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 107 110 107 110 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 132 139 132 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 191 199 <span type="species:ncbi:9606">children</span>
The calculated allele frequencies were 73.5% for fl-GHR vs. 26.5% for d3-GHR in the SGA population and 73% vs. 27% in the controls. Table 1 shows the distribution of the genotypes in the SGA children and in the controls.
###end p 36
###begin title 37
GHR exon 3 genotypes and clinical characteristics
###end title 37
###begin p 38
###xml 139 142 137 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 180 181 176 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 232 233 226 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 339 342 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 11 19 <span type="species:ncbi:9606">children</span>
In the SGA children, the mean birthweight in SDS was significantly lower in the d3/d3 group than in the two other groups: -2.6 +/- 0.7 SDS vs. -2.2 +/- 0.9 SDS in the fl/d3 group (P = 0.016) and -2.2 +/- 0.7 SDS in the fl/fl group (P = 0.034). This difference was not present in the control population: -0.5 +/- 0.8 SDS in the d3/d3 group vs. -0.3 +/- 1.0 in the fl/d3 group and -0.4 +/- 1.0 in the fl/fl group.
###end p 38
###begin p 39
There was no significant difference in birth length, age, height and weight at start of GH treatment, parental heights and spontaneous height velocity between the three different genotype groups.
###end p 39
###begin title 40
###xml 55 63 <span type="species:ncbi:9606">children</span>
GHR exon 3 genotypes and response to rhGH in short SGA children
###end title 40
###begin p 41
###xml 270 271 270 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 281 287 281 287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
###xml 326 327 326 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 365 372 365 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
###xml 172 180 <span type="species:ncbi:9606">children</span>
The change in height velocity during the first and the second year was not significantly different between the three groups. However, the combined group of d3/d3 and d3/fl children (group D) showed a significantly higher change of growth velocity during the first year (P = 0.038, Fig. 1), second year (0.041) and both years (P = 0.03). Data are shown in detail in Table 2.
###end p 41
###begin p 42
Growth velocities (cm/year) and changes in growth velocities before and during the first 2 years of GH treatment. Data are presented as median (range)
###end p 42
###begin p 43
D, the combination of the two groups fl/d3 and d3/d3; GV0, growth velocity before GH treatment; GV1, growth velocity during the first year of GH treatment; GV2, growth velocity during the second year of GH treatment; (GV1 + GV2)/2, mean growth velocity during the first 2 years of GH treatment.
###end p 43
###begin p 44
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P = 0.038 between fl/fl and D groups.
###end p 44
###begin p 45
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P = 0.041 between fl/fl and D groups.
###end p 45
###begin p 46
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P = 0.03 between fl/fl and D groups.
###end p 46
###begin p 47
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P = 0.04 indicates significant difference between observed and predicted growth velocity using the SGA prediction model.
###end p 47
###begin p 48
###xml 79 87 <span type="species:ncbi:9606">children</span>
Change in growth velocity during the first year of GH treatment in the 240 SGA children according to the dose of rhGH: high dose 0.43 +/- 0.17 mg/kg/week; low dose 0.21 +/- 0.04 mg/kg/week. Results are presented as boxes with the horizontal line inside the box representing the mean and the vertical line representing the interquartile range (10th-90th centiles). The extreme values are presented as circles. The d3/d3 + fl/d3 group (or D group) is in white and the fl/fl group is in grey.
###end p 48
###begin p 49
###xml 80 81 80 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 103 104 103 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 212 213 212 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 254 260 254 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
###xml 20 28 <span type="species:ncbi:9606">children</span>
When we divided the children into two groups according to rhGH dose [high dose (n = 197) and low dose (n = 43)], a significant change in growth velocity during the first year was observed in the high-dose group (P = 0.027) but not in the low-dose group (Fig. 1).
###end p 49
###begin p 50
###xml 67 68 67 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 198 204 198 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2</xref>
###xml 97 105 <span type="species:ncbi:9606">children</span>
Studentized residuals in the fl/fl group were significantly lower (P = 0.04), meaning that these children grew less than predicted, while they was no significant difference in the other two groups (Fig. 2).
###end p 50
###begin p 51
###xml 121 122 121 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 646 647 646 647 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Studentized residuals in the three genotype groups are calculated according to the KIGS growth prediction model for SGA, 2 incorporating rhGH dose, age and weight at start of therapy as well as gender-adjusted midparental height. Results are presented as boxes with the horizontal line inside the box representing the mean and the vertical line representing the interquartile range (10th-90th centiles). Positive studentized residuals indicate growth that exceeded the prediction, negative values growth below the prediction. The asterisk indicates a significant difference between the predicted growth velocity and the observed growth velocity (P = 0.04).
###end p 51
###begin title 52
Discussion
###end title 52
###begin p 53
###xml 115 123 <span type="species:ncbi:9606">children</span>
We took the opportunity of the NESTEGG project to analyse a subgroup of this population with prepubertal short SGA children treated with rhGH for 1 or 2 years.
###end p 53
###begin p 54
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 646 647 646 647 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 57 65 <span type="species:ncbi:9606">children</span>
###xml 250 258 <span type="species:ncbi:9606">children</span>
###xml 323 331 <span type="species:ncbi:9606">children</span>
###xml 383 391 <span type="species:ncbi:9606">children</span>
###xml 621 629 <span type="species:ncbi:9606">children</span>
This study, of a large multinational cohort of short SGA children, is unique and showed the association of the exon 3 GHR polymorphism with rhGH responsiveness in the largest population reported so far. In the first study, 6 performed in France, SGA children represented 35% of the study population (60 SGA among 172 short children). Another study was performed in Germany in 60 SGA children.7 In both studies the exon 3 GHR polymorphism was associated with rhGH responsiveness. Conversely, a more recent publication did not report any significant difference in GH responsiveness in a large Spanish population of 170 SGA children and adolescents.8
###end p 54
###begin p 55
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 354 355 354 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 471 472 471 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 575 577 575 577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 587 588 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 951 952 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 313 321 <span type="species:ncbi:9606">children</span>
###xml 536 544 <span type="species:ncbi:9606">children</span>
###xml 589 597 <span type="species:ncbi:9606">children</span>
We did not find a significantly higher growth velocity in the d3/d3 group as published.7 Nevertheless, we did find a significant larger change in growth velocity, only in the mixed group of homozygotes and heterozygotes, during the first year and the first 2 years of GH treatment in this population of short SGA children, as reported in the first study.6 This suggests the involvement of other factors. In another study combining different populations with short stature7 (Turner and SGA), the effect of this polymorphism in short SGA children was lower than in GH-deficient15 or Turner7 children in terms of growth velocity. The influence of the exon 3 GHR polymorphism in SGA became more evident when growth was analysed by the SGA growth prediction model, which takes into consideration the variability of the response to treatment between individuals. The magnitude of the difference is small but in the same range as in the previous publication.7
###end p 55
###begin p 56
###xml 273 276 271 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 260 268 <span type="species:ncbi:9606">children</span>
In our study, the association of the exon 3 GHR polymorphism with growth responsiveness was observed in the group with the higher rhGH dose (0.43 +/- 0.17 mg/kg/week). The lack of significance in the group with a lower dose could be due to the small number of children (43 vs. 197).
###end p 56
###begin p 57
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
###xml 399 400 399 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 402 403 402 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b16">16</xref>
Discordant results regarding the exon 3 GHR polymorphism and rhGH responsiveness have also been reported a in GH-deficient population.15, 16 The NESTEGG cohort is a multinational cohort, which could reduce the effect of specific population polymorphisms. The distribution of the three genotypes is not significantly different in this study compared to the different reports in Caucasian populations.6, 7, 16
###end p 57
###begin p 58
###xml 208 210 208 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
In our study, the frequency of the d3-GHR variant was comparable in the SGA and in the controls, suggesting that this polymorphism is not primarily related to the genesis of SGA. However, a recent publication17 performed in a Spanish population reported a significantly higher frequency of the fl/fl genotype in SGA compared to controls.
###end p 58
###begin p 59
In our study, birthweight was significantly lower in the d3/d3 group, while this difference was not observed in the controls. As the expression of the GHR is low before birth, it is unlikely that this difference is due to the exon 3 GHR polymorphism.
###end p 59
###begin p 60
###xml 138 146 <span type="species:ncbi:9606">children</span>
Our data, based on a large cohort, showed that the exon 3 GHR polymorphism is associated with the responsiveness to rhGH treatment in SGA children with short stature. However, given the contradictory findings in other reports, this polymorphism is probably not a major factor among those influencing GH response.
###end p 60
###begin title 61
References
###end title 61
###begin article-title 62
###xml 59 67 <span type="species:ncbi:9606">children</span>
Recombinant growth hormone for idiopathic short stature in children and adolescents
###end article-title 62
###begin article-title 63
###xml 60 68 <span type="species:ncbi:9606">children</span>
Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database)
###end article-title 63
###begin article-title 64
A mathematical model for predicting growth response to growth hormone replacement therapy - a useful clinical tool or an intellectual exercise?
###end article-title 64
###begin article-title 65
Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution
###end article-title 65
###begin article-title 66
###xml 57 62 <span type="species:ncbi:9606">human</span>
Expression and binding properties of two isoforms of the human growth hormone receptor
###end article-title 66
###begin article-title 67
A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone
###end article-title 67
###begin article-title 68
###xml 118 126 <span type="species:ncbi:9606">children</span>
The d3-growth hormone receptor polymorphism is associated with increased responsiveness to GH in Turner and short SGA children
###end article-title 68
###begin article-title 69
###xml 199 207 <span type="species:ncbi:9606">children</span>
###xml 277 285 <span type="species:ncbi:9606">patients</span>
The d3/fl-growth hormone (GH) receptor polymorphism does not influence the effect of GH treatment (66 microg/kg per day) or the spontaneous growth in short non-GH-deficient small-for-gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients
###end article-title 69
###begin article-title 70
NESTEGG: aims and strategies. Northern European Study of Genes in Growth
###end article-title 70
###begin article-title 71
###xml 49 54 <span type="species:ncbi:9606">girls</span>
Variations in the pattern of pubertal changes in girls
###end article-title 71
###begin article-title 72
###xml 49 53 <span type="species:ncbi:9606">boys</span>
Variations in the pattern of pubertal changes in boys
###end article-title 72
###begin article-title 73
Cross sectional stature and weight reference curves for the UK, 1990
###end article-title 73
###begin article-title 74
###xml 99 107 <span type="species:ncbi:9606">children</span>
Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. II
###end article-title 74
###begin article-title 75
###xml 99 107 <span type="species:ncbi:9606">children</span>
Standards from birth to maturity for height, weight, height velocity, and weight velocity: British children, 1965. I
###end article-title 75
###begin article-title 76
###xml 56 64 <span type="species:ncbi:9606">children</span>
The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor
###end article-title 76
###begin article-title 77
###xml 137 145 <span type="species:ncbi:9606">patients</span>
Growth hormone (GH) pharmacogenetics: influence of GH receptor 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency
###end article-title 77
###begin article-title 78
###xml 160 161 160 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 205 206 205 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 134 142 <span type="species:ncbi:9606">children</span>
Exon 3-deleted/full-length growth hormone receptor polymorphism genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA
###end article-title 78

